From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

AIM Regulation and Stuart Ashman: the Oxymorons don’t answer the question and I persist

By Tom Winnifrith | Tuesday 30 January 2024

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

The bearded poltroon in charge of Skinbiotherapeutics (SBTX), where I remain a loyal shareholder, says that “rules are rules” and that AIM Regulation has insisted that he cannot do a video interview with me inside a paywall. That is a lie and I am now in dialogue with the Oxymorons who so far, as you can see, are evasive. For what it is worth, hapless moron Giles Balleny at Nomad Cavendish has already been shown to be lying by events elsewhere.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Video: Poking Bears And Black Swans



Is Stuart Ashman lying again?



So farewell then

Time left: 17:50:20